Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic
Advance a New Generation of More Targeted Tissue & Antigen-Specific B Cell-Targeting Therapies to Improve Patient Quality of Life
Welcome to the 4th B&T Cell-Mediated Autoimmune Disease Drug Development Summit
Targeted B Cell Depletion & Modulation for Autoimmunity, Transplantation & Inflammation
Welcome to the 4th B&T Cell-Mediated Autoimmune Disease Drug Development Summit, the definitive industry forum sharing groundbreaking B cell R&D for drug development applications in autoimmunity.
With biopharma moving closer to developing more patient-centric therapeutic approaches in autoimmunity, this innovative community is now looking to harness the drug development potential of the B cell lineage and bring the next generation of tissue and antigen-specific therapies to patient populations who need them the most.
This December, join a community of 60+ thought leaders from the likes of Janssen, Regeneron, Biogen, Hummingbird Biosciences, Eli Lilly and more in Philadelphia, PA, to advance the discovery, development and optimization of a new generation of B cell-directed therapies!
Register your interest now to perfect your targeted B cell depletion and modulating therapies, optimize tissue subset analysis and accessibility and grasp the therapeutic potential of novel cell types such as B regulatory, B memory and plasma cells to drive your mono and combined modality approaches into the clinic and beyond.
Previous Attending Companies Include:
‘The value for me resides in that this is a focused conference centred around important translational topics which themselves represent the current and future challenges of drug development in autoimmunity.’
Bristol Myers Squibb
Other Events in the Series:
